Industry reports
Editor highlights

Pathology Analysis & Statistics in the United Kingdom, April 2014

You might be interested in: cancer, breast cancer, prostate cancer, more »

» Purchase Premium Reports

1-50 of about 2 600 reports
PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022

  • $ 6 995
  • Industry report
  • February 2014
  • by Global Data

PharmaPoint: Schizophrenia - 5EU Drug Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, United Kingdom, Europe
EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • April 2014
  • by Global Data

EpiCast Report: Allergic Rhinitis - Epidemiology Forecast to 2023 Summary Allergic rhinitis is a chronic respiratory disease characterized by inflammation of the nasal cavity and affects people of all ...

  • Industries : Pathology
  • Countries : Japan, World, Spain, Italy, France, Germany, United States, United Kingdom
Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Seroquel (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Germany, Spain, Italy, France, Japan, World, Europe, United States, United Kingdom
Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Risperdal (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Aripiprazole Lauroxil (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Cariprazine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Brexpiprazole (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zicronapine (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Bitopertin (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

EVP-6124 (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Abilify (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Saphris (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, Germany, Japan, World, United States, United Kingdom
Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Clozaril (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Latuda (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Invega (Schizophrenia) - Forecast and Market Analysis to 2022

Invega (Schizophrenia) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • February 2014
  • by Global Data

Invega (Schizophrenia) - Forecast and Market Analysis to 2022 Summary Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, Japan, World, United States, United Kingdom, Europe
Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Stelara (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, India, China, Europe
Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • January 2014
  • by Global Data

Vercirnon (Crohn's Disease) - Forecast and Market Analysis to 2022 Summary The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will ...

  • Industries : Pathology
  • Countries : Canada, World, Spain, Italy, France, Germany, United States, United Kingdom, India, China, Europe
Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

Cancer Research UK SWOT Analysis, Strategy, Revenues and Profits

  • $ 300
  • Company report
  • February 2014
  • by Global Data

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in ...

  • Industries : Pathology
  • Countries : United Kingdom
British Columbia Cancer Agency - Pharmaceuticals & Healthcare - Deals and Alliances Profile

British Columbia Cancer Agency - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • February 2014
  • by Global Data

Summary British Columbia Cancer Agency (BCCA) is a healthcare service providing company. The company provides cancer care program which includes prevention, screening and early detection, diagnosis and ...

  • Industries : Pathology
  • Countries : United Kingdom
H. Lundbeck AS (LUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

H. Lundbeck AS (LUN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Industry report
  • February 2014
  • by Global Data

Summary H. Lundbeck A/S (Lundbeck) is a pharmaceutical company, involved in the research, development, manufacturing and marketing of pharmaceuticals for the treatment of diseases related to the central ...

  • Industries : Pathology
  • Countries : United States, Denmark, United Kingdom, Ireland
Advanced Life Sciences Holdings, Inc. (ADLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Advanced Life Sciences Holdings, Inc. (ADLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Industry report
  • February 2014
  • by Global Data

Summary Advanced Life Sciences Holdings, Inc. (Advanced Life Sciences) engages in the discovery, development, and commercialization of drugs in the areas of infectious disease, inflammation, and oncology. ...

  • Industries : Pathology
  • Countries : United States, United Kingdom
University of London - Pharmaceuticals & Healthcare - Deals and Alliances Profile

University of London - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary University of London (UOL) is an educational service provider. The university provides educational courses in various areas. Its business services include academic skills training, career development ...

  • Industries : Pathology
  • Countries : United Kingdom
Institute of Cancer Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Institute of Cancer Research - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary Institute of Cancer Research (ICR) is a cancer research center. The center research and develops material transfer of technology used for cancer prevention, diagnosis and treatment. Its activities ...

  • Industries : Pathology
  • Countries : United Kingdom
Cancer Research UK - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cancer Research UK - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary Cancer Research UK (CRUK) is a research center. The center provides services in cancer research. Its research areas include biology of cancer cells and cancer prevention. CRUK tests treatments ...

  • Industries : Pathology
  • Countries : United Kingdom
Cancer Research Technology Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cancer Research Technology Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • $ 250
  • Company report
  • January 2014
  • by Global Data

Summary Cancer Research Technology Limited (CRT), formerly known as Cancer Research Campaign Technology Limited, is a cancer technology company. It operates as cancer-focused technology development and ...

  • Industries : Pathology
  • Countries : United Kingdom
Abcodia Ltd. - Product Pipeline Analysis, 2013 Update

Abcodia Ltd. - Product Pipeline Analysis, 2013 Update

  • $ 750
  • Company report
  • December 2013
  • by Global Data

Summary Abcodia Ltd. (Abcodia) is a biomarker validation company. The company validates and discovers biomarkers for early diagnosis and screening of cancer. It concentrates in the detection of colorectal ...

  • Industries : Pathology
  • Countries : United Kingdom
EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022

  • $ 3 995
  • Industry report
  • December 2013
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2022 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • December 2013
  • by Global Data

Lucentis (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, ...

  • Industries : Pathology
  • Countries : Japan, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe
Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

  • $ 3 495
  • Industry report
  • December 2013
  • by Global Data

Avastin (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, ...

  • Industries : Pathology
  • Countries : Japan, Spain, Italy, France, Germany, World, United States, United Kingdom, Europe

» View Public Reports

About 500 reports

The United Kingdom: Country Brief, 2013-2014, focus on Pathology

  • Country report
  • December 2013
  • 4 pages

... Adverse event occur. In the case of products such as income protection (and partial payments on critical illness policies) moreover, benefits are available again should a subse- quent event or events arise ...


» Read our Company Profiles

6 Companies

GlaxoSmithKline P.L.C.

United States

Management Strategies

United States

Abbott Laboratories

United States

Eli Lilly and Co.

United States

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.